Real-time PCR measurement of gene expression showed that both angiogenesis-related factors (VEGF, matrix metalloproteinase-2 [MMP2], and matrix metalloproteinase-9 [MMP9]) and inflammation-related factors (SDF1 and tumor necrosis factor-alpha [TNF-α]) were significantly repressed in PSP-treated corneas compared to control corneas whereas the anti-angiogenic factor, PEDF, was upregulated in PSP-treated corneas when compared to the control corneas (Figure 5). The gene discussed is MMP9; the disease is supranuclear palsy, progressive, 1.